Mounjaro Vomiting That Won't Go Away: When to Worry and What to Do

How common is vomiting on Mounjaro?

In the two placebo-controlled trials the label pools for adults with type 2 diabetes, SURPASS-1 (tirzepatide as monotherapy) and SURPASS-5 (tirzepatide added to basal insulin), vomiting was reported by 2% of patients on placebo and by 5% on 5 mg, 5% on 10 mg and 9% on 15 mg [1]. A total of 718 patients received Mounjaro, with a mean exposure of 36.6 weeks [1].

Gastrointestinal reactions as a group were reported by 20.4% of placebo patients versus 37.1%, 39.6% and 43.6% of the 5, 10 and 15 mg groups, and treatment was stopped for a GI reaction by 0.4% of placebo patients versus 3.0%, 5.4% and 6.6% [1]. Severe GI reactions were reported by 0.9% of placebo patients and by 1.3% (5 mg), 0.4% (10 mg) and 1.2% (15 mg) of Mounjaro patients [1].

Rates look different in other trial populations. In the cardiovascular outcomes trial that exposed 6,647 adults with type 2 diabetes and established cardiovascular disease to Mounjaro, vomiting was reported in 12% [1]. In SURPASS-2, an open-label 40-week trial of 1,879 adults with type 2 diabetes on metformin, vomiting was reported in 6% to 10% of the tirzepatide arms and 8% of the semaglutide 1 mg arm [2]. The Mounjaro label cautions that adverse-reaction rates from different clinical trials cannot be directly compared [1].

Does the vomiting stop once the dose stays the same?

The label's own summary is that the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. The schedule is 2.5 mg once weekly to start, then increases of 2.5 mg after at least 4 weeks on the current dose if more glycemic control is needed, to a maximum of 15 mg weekly in adults and 10 mg weekly in children 10 years and older [1]. The label says to follow that schedule to reduce the risk of gastrointestinal adverse reactions [1]. It does not put a week number on when vomiting stops.

Which symptoms change the picture?

The label's warnings matter at any dose, including during escalation.

Dehydration and kidney injury. There are postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Mounjaro; the majority occurred in patients who had gastrointestinal reactions leading to dehydration, such as nausea, vomiting or diarrhea [1]. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Acute pancreatitis. Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists and with Mounjaro [1]. The label describes the presentation as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Mounjaro if pancreatitis is suspected [1].

Gallbladder disease. Acute gallbladder events (cholelithiasis, biliary colic and cholecystectomy) were reported by 0.6% of Mounjaro-treated patients and 0% of placebo patients in the adult placebo-controlled trials [1]. If cholelithiasis is suspected, the label calls for gallbladder studies and clinical follow-up [1].

Severe gastroparesis. Mounjaro is not recommended in patients with severe gastroparesis [1]. Tirzepatide delays gastric emptying [1].

What about a lower dose?

The Mounjaro label says to increase the dose by 2.5 mg only if additional glycemic control is needed, after at least 4 weeks on the current dose [1]. In SURPASS-5, HbA1c fell by a mean 2.11 percentage points with 5 mg of tirzepatide added to insulin glargine, versus 0.86 points with placebo, while the 10 mg and 15 mg arms fell 2.40 and 2.34 points. The trial-wide mean baseline HbA1c was 8.31% [3].